
Microbiology/Medicine @UniAndes, Internal Medicine @FSFB_salud, Hematology @HematoCAUSA. BMTU attending @ICO_oncologia @HematICO_Hosp #HSCT #CARTcells #GvHD #ID
Hospitalet de Llobregat, Spain
Joined April 2018
- Tweets10.4K
- Following1.2K
- Followers2K
- Likes16.6K
Pinned Tweet
My true meaning of happiness and life! This is what I meant to be! This is where I have to be! Where I belong! No doubt about it! #HematoLife #Hematology #Thankful #HematoRules #HematoForever #PorHematoMato #HematoMola
Felipe Peña-Muñoz retweeted
🤝Proud to launch a new joint educational initiative between @GETH_info and @TheEBMT Infectious Diseases Working Party. This international webinar series will bring together leading experts to address key infectious complications in #HSCT & @CellTherapy and cellular therapy.
Felipe Peña-Muñoz retweeted
Para los que dicen o creen que los médicos colombianos formados en universidades del país salen corriendo la mayoría porque no quieren trabajar aquí mejor revisen el dato de OCDE. Tasa de expatriación 7.4%. La mayoría nos quedamos a trabajar por el país y por una mejor sociedad.
Felipe Peña-Muñoz retweeted
L'@ICO_oncologia busca un/a Metge/ssa especialista per a la Unitat d'Hospitalització i Atenció Continuada Oncològica (UACO) de l'#ICO #Badalona @hgermanstrias
🩺 Assistència, docència, recerca i treball multidisciplinari en un centre de referència.
icogencat.talentclue.com/ca/…
Más que necesario y ahora más que nunca con los grandes avances recientes que ha tenido la Hematología! 🩸
#Medicina | 🩺 Armando López Guillermo, nuevo presidente de la @sehh_es, plantea ampliar a cinco años la formación #MIR en #Hematología
consalud.es/profesionales/me…
Another great paper from @SergioRdzRdz
onlinelibrary.wiley.com/doi/…
Felipe Peña-Muñoz retweeted
Are we curing patients with r/r DLBCL using BsAb monotherapy beyond 2L?
#ASH26
5-year outcomes with glofitamab:
• DoCR: 46%
• 5-year PFS: 19.3%
• 5-year OS: 28.1%
Perhaps the most democratic form of innovation in lymphoma: potentially curative, off-the-shelf, and not dependent on CAR-T infrastructure!
Excelente explicación!
1/9 —¿Más médicos extranjeros que españoles en el #MIR2027? 🩺
El dato que corre como la pólvora en redes es real… pero está contado a medias.
Desmontamos con datos oficiales qué hay de cierto y qué es manipulación en el vídeo viral sobre el MIR. 🧵⬇️
8
1,996
Felipe Peña-Muñoz retweeted
5/9 —
3️⃣ El cupo del 10% NO es nuevo
Se dice que el Gobierno lo subió del 4% al 10% para favorecer a extranjeros. Falso por fechas:📌 El tope del 10% existe desde el RD 183/2008.
📌 El 4% fue puntual en 2013-2014.
📌 En 2027 son 968 plazas de un récord total de 9.676.
Felipe Peña-Muñoz retweeted
3/9 — Datos
1️⃣ Solicitudes ≠ Admitidos
Es cierto que hubo más solicitudes extranjeras (12.569) que españolas (11.573). Primera vez que pasa.
PERO en las listas provisionales de Sanidad, los españoles son mayoría:
🇪🇸 Admitidos: 11.126 (51,35%)
🌍 Admitidos: 10.542 (48,65%)
Felipe Peña-Muñoz retweeted
En mi experiencia personal, tras haber visto pasar muchas promociones de residentes, los que provenían de Hispanoamérica (Argentina, Ecuador, Rep.Dominicana y Colombia) venían perfectamente preparados y en algunas cuestiones básicas, que aquí dejamos a enfermería, incluso mejor.
Felipe Peña-Muñoz retweeted
#ASH26 #bmtsm
#1061 (Oral): Adding MMF to PTCy-CNI in matched-donor HCT (Saliba; n=2,771, registry)
- MMF had no benefit on any endpoint (GRFS HR 1.03).
- Trend toward harm with matched sibling donors (relapse HR 1.51) and more chronic GVHD overall (HR 1.34).
- Supports dropping MMF for matched donors
Felipe Peña-Muñoz retweeted
GUÍAS ASH 2026: TROMBOCITOPENIA INMUNE EN ADULTOS 🧵
➡️Tratamiento inicial y de segunda línea
📌Ya NO se sugiere esteroide solo como 1ª línea
✅Esteroide + rituximab o + agente trombopoyético
📍Algoritmo de tratamiento
doi: 10.1182/bloodadvances.2026021269
See you soon everyone!
Next Thursday, Madrid! 🦠🧫🧠🧬
@TheEBMT @TheEBMT_Trainee
Felipe Peña-Muñoz retweeted
🩸 Chronic GVHD | When can we stop systemic therapy?
🎙️ Take-home points from Dr. Mohammed Alzahrani at BMT & CGT 2026.
📊 About one-third of patients in a long-term cohort were alive and off systemic immunosuppression at roughly 5 years. Of those who stopped at least once, about half restarted, at a median of 3.4 months. Follow closely during the first 3–6 months after stopping.
⏳ Durable withdrawal can take years. Among patients who achieved at least 12 months off systemic therapy, the median time from chronic GVHD diagnosis to durable discontinuation was 3.6 years.
🫁 Who may have a harder time stopping? Higher NIH global severity, lung involvement, extensive deep sclerosis, and oral or skin involvement have been associated with a lower likelihood of successful withdrawal.
💊 Individualize the taper. Randomized evidence on when and how to stop remains limited. Document baseline organ findings and give patients a written plan for symptoms to report and whom to contact. During a steroid taper, new fatigue, weakness or nausea also warrants consideration of adrenal insufficiency or glucocorticoid withdrawal.
#ChronicGVHD #GVHD #AlloHSCT #BMT #KFSHRC
#destacadoSEHH | “Los hematólogos deben adquirir una cierta alfabetización en IA” univadis.es/viewarticle/hema…
Felipe Peña-Muñoz retweeted
🏆 Otro galardón para el #Hospital12deOctubre!
👏 Premio Best in Class al Mejor Servicio de Medicina Intensiva, por su excelencia en innovación, seguridad y humanización de atención al paciente crítico.
🔝 Compromiso y trabajo en equipo.
🔗 c.madrid/2rabq
#somosdel12
Excellent post! Very important in our daily practice! #HSCT
💊 Immunosuppressant interactions after allo-HSCT | What to adjust, avoid and monitor
🎙️ Presented by Dr. Deemah Almolaiki at BMT & CGT 2026.
🛡️ Across the transplant course. GVHD prophylaxis is protocol-specific and may include tacrolimus or cyclosporine with methotrexate or mycophenolate, or a post-transplant cyclophosphamide–based regimen. Systemic corticosteroids are first-line when acute GVHD requires systemic therapy and for moderate-to-severe chronic GVHD. Ruxolitinib (Jakafi/Jakavi) is a standard option for steroid-refractory GVHD.
🍄 Voriconazole (Vfend) and posaconazole (Noxafil). When either is started in a patient already on tacrolimus (Prograf), the U.S. labels recommend reducing tacrolimus to one-third of the previous dose and monitoring troughs closely. Both azoles are contraindicated with sirolimus (Rapamune) under U.S. labeling. When an azole is stopped or switched, recheck levels and retitrate as inhibition wanes.
🦠 Letermovir (Prevymis) has several interactions at once. In adults receiving cyclosporine, use letermovir 240 mg once daily instead of 480 mg and monitor cyclosporine levels. Letermovir can also raise tacrolimus and sirolimus exposure and lower voriconazole exposure. Maribavir (Livtencity) can raise tacrolimus levels too. Plan level checks when these antivirals are started or stopped.
🚨 Nirmatrelvir/ritonavir (Paxlovid). Ritonavir can sharply raise tacrolimus and cyclosporine exposure. Use with a calcineurin inhibitor requires a transplant pharmacy plan and close level monitoring during and after therapy. Avoid the combination if that monitoring is unavailable. U.S. labeling advises avoiding concomitant sirolimus or everolimus.
🔄 Interactions within the regimen. When cyclosporine and sirolimus are prescribed together, give sirolimus 4 hours after cyclosporine. Switching from cyclosporine to tacrolimus can increase mycophenolic acid exposure. PPIs can lower exposure from mycophenolate mofetil (CellCept), so review the need for acid suppression and the formulation.
🎯 Two GVHD treatment pearls. With ruxolitinib, avoid fluconazole >200 mg/day under U.S. labeling. At lower doses, check the label for the applicable dose modification. For belumosudil (Rezurock), the labeled dose increases from 200 mg once daily to 200 mg twice daily with a PPI or a strong CYP3A inducer.
📉 Check the rest of the medication list. Rifampin and enzyme-inducing anticonvulsants can lower calcineurin inhibitor or sirolimus exposure. Clarithromycin, erythromycin, diltiazem and verapamil can raise it. Review troughs after significant steroid taper steps and during and after aprepitant or fosaprepitant when the drugs overlap.
⚠️ Toxicity can occur with an in-range trough. Calcineurin inhibitors plus amphotericin B or aminoglycosides increase AKI risk. Mycophenolate or methotrexate can add to marrow suppression from ganciclovir or TMP-SMX. Review QT-prolonging combinations and electrolytes. On tacrolimus plus sirolimus, new hypertension, proteinuria or rising LDH should prompt evaluation for transplant-associated thrombotic microangiopathy.
🧪 At each medication change, document the dose plan and when the next trough is due. Include starts, stops, route or formulation changes, and new diarrhea or mucositis.
#AlloHSCT #GVHD #DrugInteractions #TransplantPharmacy #KFSHRC
Felipe Peña-Muñoz retweeted
💊 Immunosuppressant interactions after allo-HSCT | What to adjust, avoid and monitor
🎙️ Presented by Dr. Deemah Almolaiki at BMT & CGT 2026.
🛡️ Across the transplant course. GVHD prophylaxis is protocol-specific and may include tacrolimus or cyclosporine with methotrexate or mycophenolate, or a post-transplant cyclophosphamide–based regimen. Systemic corticosteroids are first-line when acute GVHD requires systemic therapy and for moderate-to-severe chronic GVHD. Ruxolitinib (Jakafi/Jakavi) is a standard option for steroid-refractory GVHD.
🍄 Voriconazole (Vfend) and posaconazole (Noxafil). When either is started in a patient already on tacrolimus (Prograf), the U.S. labels recommend reducing tacrolimus to one-third of the previous dose and monitoring troughs closely. Both azoles are contraindicated with sirolimus (Rapamune) under U.S. labeling. When an azole is stopped or switched, recheck levels and retitrate as inhibition wanes.
🦠 Letermovir (Prevymis) has several interactions at once. In adults receiving cyclosporine, use letermovir 240 mg once daily instead of 480 mg and monitor cyclosporine levels. Letermovir can also raise tacrolimus and sirolimus exposure and lower voriconazole exposure. Maribavir (Livtencity) can raise tacrolimus levels too. Plan level checks when these antivirals are started or stopped.
🚨 Nirmatrelvir/ritonavir (Paxlovid). Ritonavir can sharply raise tacrolimus and cyclosporine exposure. Use with a calcineurin inhibitor requires a transplant pharmacy plan and close level monitoring during and after therapy. Avoid the combination if that monitoring is unavailable. U.S. labeling advises avoiding concomitant sirolimus or everolimus.
🔄 Interactions within the regimen. When cyclosporine and sirolimus are prescribed together, give sirolimus 4 hours after cyclosporine. Switching from cyclosporine to tacrolimus can increase mycophenolic acid exposure. PPIs can lower exposure from mycophenolate mofetil (CellCept), so review the need for acid suppression and the formulation.
🎯 Two GVHD treatment pearls. With ruxolitinib, avoid fluconazole >200 mg/day under U.S. labeling. At lower doses, check the label for the applicable dose modification. For belumosudil (Rezurock), the labeled dose increases from 200 mg once daily to 200 mg twice daily with a PPI or a strong CYP3A inducer.
📉 Check the rest of the medication list. Rifampin and enzyme-inducing anticonvulsants can lower calcineurin inhibitor or sirolimus exposure. Clarithromycin, erythromycin, diltiazem and verapamil can raise it. Review troughs after significant steroid taper steps and during and after aprepitant or fosaprepitant when the drugs overlap.
⚠️ Toxicity can occur with an in-range trough. Calcineurin inhibitors plus amphotericin B or aminoglycosides increase AKI risk. Mycophenolate or methotrexate can add to marrow suppression from ganciclovir or TMP-SMX. Review QT-prolonging combinations and electrolytes. On tacrolimus plus sirolimus, new hypertension, proteinuria or rising LDH should prompt evaluation for transplant-associated thrombotic microangiopathy.
🧪 At each medication change, document the dose plan and when the next trough is due. Include starts, stops, route or formulation changes, and new diarrhea or mucositis.
#AlloHSCT #GVHD #DrugInteractions #TransplantPharmacy #KFSHRC
Felipe Peña-Muñoz retweeted
¡El talento investigador de Uniandes trasciende fronteras! Nuestros profesores Carlos Mendivil, @76Juano y @osarmien_ están en World’s Top 2% Scientists 2026, clasificación internacional que destaca el impacto de la investigación científica.
🔗 Conoce más medicina.uniandes.edu.co/es/…
Felipe Peña-Muñoz retweeted
🩺 Inscríbete en la nueva Especialización en Enfermería Oncológica de @Uniandes : acompaña al paciente y a su familia en cada etapa.
Con el respaldo de la @FSFB_Salud.
📚 Inscripciones abiertas hasta el 18 de noviembre 2026
🔗 Infórmate más: medicina.uniandes.edu.co/es/…
#Enfermería






































